



WIP 1633 + Box 529

PATENT

8/10
P. Webb
12/11/99

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231.

Date of Signature

and Deposit: December 2, 1999

Carl R. Schwartz, Reg. No. 29,437

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 09 1999

TECH CENTER 1600/2900

Applicant: James A. Thomson
Serial No.: 09/106,390
Filed: June 26, 1998
Title: PRIMATE EMBRYONIC STEM CELLS
Art Unit: 1633
Examiner: Deborah Clark

Assistant Commissioner For Patents
Washington, D.C. 20231
Attn: Box Non-Fee Amendment

Dear Sir:

In response to the September 24, 1999 Office Action and in the matter of the above-described case, please enter the following Amendment.

Amendment

In The Specification:

Entered as B2
Please replace pages 47-49 of the specification (the sequence listing) with the attached sequence listing.

In The Claims:

Please amend the claims as follows:

C
B2
5 --1. (Amended) A purified preparation of ^{Pluripotent} human embryonic stem cells which (i) will proliferate [is capable of proliferation] in an *in vitro* culture for over one year, (ii) maintains a karyotype in which [all] the chromosomes [characteristic of the human species are present] are euploid and not [noticeably] altered through prolonged culture, (iii) maintains the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues throughout the culture, and (iv) [are] is inhibited from differentiation when
10 cultured on a fibroblast feeder layer.

C
B3
3. (Amended) A purified preparation of ^{Pluripotent} human embryonic stem cells wherein the cells are [essentially] negative for the SSEA-1 marker, positive for the SSEA-4 marker, express